Madrigal Pharma (MDGL) Misses Q4 EPS by 197c
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Join SI Premium – FREE
Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.57), $1.97 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $321.1 million versus the consensus estimate of $310.82 million.
For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Rubio to visit Gulf states amid Iran deal concerns
- FDA launches Operation TrialBlazer to accelerate drug research
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
